Aloglutamol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Aloglutamol
Accession Number
DB13650
Type
Small Molecule
Groups
Approved
Description

Aloglutamol is an antacid, an aluminium compound. It is a salt of aluminium, gluconic acid, and tris. Proprietary names include Altris, Pyreses, Tasto and Sabro.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Altris / Pyreses / Sabro / Tasto
Categories
UNII
I670EI8M2N
CAS number
13755-41-4
Weight
Average: 377.2786
Monoisotopic: 377.111388678
Chemical Formula
C10H24AlNO12
InChI Key
GJJYZOBRHIMORS-GQOAHPRESA-K
InChI
InChI=1S/C6H12O7.C4H11NO3.Al.2H2O/c7-1-2(8)3(9)4(10)5(11)6(12)13;5-4(1-6,2-7)3-8;;;/h2-5,7-11H,1H2,(H,12,13);6-8H,1-3,5H2;;2*1H2/q;;+3;;/p-3/t2-,3-,4+,5-;;;;/m1..../s1
IUPAC Name
2-amino-2-(hydroxymethyl)propane-1,3-diol; dihydroxyalumanyl (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
SMILES
NC(CO)(CO)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Al](O)O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aloglutamol.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Aloglutamol.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineAloglutamol may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAloglutamol may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineAloglutamol may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAloglutamol may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Aloglutamol.Experimental, Illicit
AcepromazineAloglutamol can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineAloglutamol can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetaminophenAloglutamol can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Aloglutamol.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Aloglutamol.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Aloglutamol.Approved
AlimemazineAloglutamol can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolAloglutamol can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Aloglutamol.Approved
AmphetamineAloglutamol may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Aloglutamol.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Aloglutamol.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Aloglutamol.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Aloglutamol.Investigational
AtazanavirAloglutamol can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Aloglutamol.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aloglutamol.Approved, Investigational
BenzphetamineAloglutamol may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Aloglutamol.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aloglutamol.Approved
Bismuth subcitrate potassiumThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Aloglutamol.Approved, Investigational
BL-1020Aloglutamol can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Aloglutamol.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Aloglutamol.Approved
CaptoprilAloglutamol can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Aloglutamol.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Aloglutamol.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Aloglutamol.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Aloglutamol.Approved, Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Aloglutamol.Approved, Investigational, Vet Approved
ChlorphentermineAloglutamol may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineAloglutamol can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineAloglutamol can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineAloglutamol can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Aloglutamol.Approved, Investigational
CinoxacinAloglutamol can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Aloglutamol.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Aloglutamol.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Aloglutamol.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Aloglutamol.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Aloglutamol.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Aloglutamol.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Aloglutamol.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Aloglutamol.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Aloglutamol.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aloglutamol.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Aloglutamol.Approved, Investigational
DasatinibAloglutamol can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Aloglutamol.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Aloglutamol.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Aloglutamol.Approved
DemeclocyclineAloglutamol can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Aloglutamol.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Aloglutamol.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Aloglutamol.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Aloglutamol.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Aloglutamol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Aloglutamol.Vet Approved
DexmethylphenidateAloglutamol can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineAloglutamol may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionAloglutamol may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Aloglutamol.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Aloglutamol.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Aloglutamol.Approved
Dipotassium phosphateAloglutamol can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Aloglutamol.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Aloglutamol.Approved
DoxycyclineAloglutamol can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Aloglutamol.Approved
EnoxacinAloglutamol can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Aloglutamol.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Aloglutamol.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Aloglutamol.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Aloglutamol.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Aloglutamol.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Aloglutamol.Approved
Ferric CarboxymaltoseAloglutamol can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateAloglutamol can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Aloglutamol.Approved, Investigational
FleroxacinAloglutamol can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluasteroneThe bioavailability of Fluasterone can be decreased when combined with Aloglutamol.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Aloglutamol.Approved, Investigational
FlumequineAloglutamol can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Aloglutamol.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Aloglutamol.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aloglutamol.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Aloglutamol.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Aloglutamol.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Aloglutamol.Approved, Investigational
FluphenazineAloglutamol can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Aloglutamol.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Aloglutamol.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Aloglutamol.Approved
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Aloglutamol.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Aloglutamol.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Aloglutamol.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Aloglutamol.Approved, Investigational, Withdrawn
FosinoprilAloglutamol can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Aloglutamol.Approved, Investigational
GarenoxacinAloglutamol can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinAloglutamol can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Aloglutamol.Approved, Investigational
GemifloxacinAloglutamol can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineAloglutamol may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aloglutamol.Approved, Investigational
GrepafloxacinAloglutamol can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Aloglutamol.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Aloglutamol.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Aloglutamol.Approved, Vet Approved
Hydrocortisone acetateThe bioavailability of Hydrocortisone acetate can be decreased when combined with Aloglutamol.Approved, Vet Approved
Hydrocortisone butyrateThe bioavailability of Hydrocortisone butyrate can be decreased when combined with Aloglutamol.Approved, Vet Approved
HydroxyamphetamineAloglutamol may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineAloglutamol can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Aloglutamol.Approved, Investigational
Iofetamine I-123Aloglutamol may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronAloglutamol can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAloglutamol can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateAloglutamol can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidAloglutamol can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Aloglutamol.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Aloglutamol.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Aloglutamol.Approved, Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Aloglutamol.Approved
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aloglutamol.Approved
LevofloxacinAloglutamol can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineAloglutamol may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinAloglutamol can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Aloglutamol.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Aloglutamol.Approved, Investigational
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Aloglutamol.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Aloglutamol.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aloglutamol.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Aloglutamol.Approved, Investigational, Vet Approved
ME-609The bioavailability of ME-609 can be decreased when combined with Aloglutamol.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Aloglutamol.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Aloglutamol.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Aloglutamol.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Aloglutamol.Approved, Investigational
MephedroneAloglutamol may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineAloglutamol may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aloglutamol.Approved
MesoridazineAloglutamol can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineAloglutamol may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Aloglutamol.Approved, Vet Approved
MethotrimeprazineAloglutamol can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineAloglutamol may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueAloglutamol can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateAloglutamol can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Aloglutamol.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Aloglutamol.Experimental
MidomafetamineAloglutamol may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aloglutamol.Approved, Vet Approved
MinocyclineAloglutamol can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Aloglutamol is combined with Misoprostol.Approved
MMDAAloglutamol may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Aloglutamol.Approved, Vet Approved
MoricizineAloglutamol can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidAloglutamol can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidAloglutamol can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Aloglutamol.Investigational
NemonoxacinAloglutamol can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Aloglutamol.Approved, Investigational
NorfloxacinAloglutamol can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinAloglutamol can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Aloglutamol.Investigational
Oxolinic acidAloglutamol can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineAloglutamol can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Aloglutamol.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Aloglutamol.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Aloglutamol.Approved
PazufloxacinAloglutamol can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinAloglutamol can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Aloglutamol.Approved
PerazineAloglutamol can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerphenazineAloglutamol can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineAloglutamol may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidAloglutamol can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidAloglutamol can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Aloglutamol.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Aloglutamol.Approved, Investigational, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Aloglutamol.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Aloglutamol.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Aloglutamol.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Aloglutamol.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Aloglutamol.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Aloglutamol.Approved, Experimental, Investigational
ProchlorperazineAloglutamol can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineAloglutamol can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineAloglutamol can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineAloglutamol can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineAloglutamol can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinAloglutamol can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineAloglutamol may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineAloglutamol may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Aloglutamol.Approved
RifampicinAloglutamol can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Aloglutamol.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Aloglutamol.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Aloglutamol.Approved, Investigational
RitobegronAloglutamol may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinAloglutamol can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinAloglutamol can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RufloxacinAloglutamol can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Aloglutamol.Approved
SitafloxacinAloglutamol can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateAloglutamol can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aloglutamol.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Aloglutamol.Approved
SparfloxacinAloglutamol can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Aloglutamol.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Aloglutamol.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Aloglutamol.Approved
Technetium Tc-99m oxidronateThe serum concentration of Technetium Tc-99m oxidronate can be increased when it is combined with Aloglutamol.Approved
TemafloxacinAloglutamol can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineAloglutamol can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiazinamAloglutamol can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineAloglutamol can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineAloglutamol can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineAloglutamol can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Aloglutamol.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Aloglutamol.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Aloglutamol is combined with Tolevamer.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Aloglutamol.Approved, Vet Approved
TriethylenetetramineAloglutamol can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineAloglutamol can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineAloglutamol can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinAloglutamol can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Aloglutamol.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Aloglutamol.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
28426726
ChEMBL
CHEMBL3707299
Wikipedia
Aloglutamol
ATC Codes
A02AB06 — Aloglutamol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-4.3ChemAxon
pKa (Strongest Acidic)11.68ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area167.91 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity42.47 m3·mol-1ChemAxon
Polarizability21.73 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar acids and derivatives
Alternative Parents
Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Monosaccharides / Secondary alcohols / 1,2-aminoalcohols / Carboxylic acid salts / Polyols / Carboxylic acids
show 10 more
Substituents
Gluconic_acid / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Hydroxy fatty acid / Fatty acyl / Fatty acid / Hydroxy acid / Monosaccharide / 1,2-aminoalcohol
show 22 more
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:46 / Updated on August 02, 2018 06:56